drugset / Trial / NCT04806113
COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases
Phase 3
Completed
220 enrolled
McGill University Health Centre/Research Institute of the McGill University Health Centre
CHU de Quebec-Universite Laval · collabMinistere de la Sante et des Services Sociaux · collab
NaSingle-groupOpen-labelPrevention
Summary
This study will evaluate the Moderna RNA-based COVID-19 vaccine currently approved by Health Canada in people with rheumatic diseases. This study will help understand what the side effects of the vaccine in these patients are, and what is their capacity to develop antibodies that may confer protection from the COVID-19 disease.
Timeline
- Start
- 2021-03-11
- Primary completion
- 2021-06-13
- Completion
- 2022-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elasomeran | Messenger RNA (mRNA) | — | Intramuscular |